Abstract
Background:
Immunoglobulin G4-related sclerosing cholangitis (IgG4-SC), also termed IgG4-related cholangitis (IRC), is a challenging immune-mediated biliary disease, frequently mimicking malignancies such as cholangiocarcinoma (CCA) or other sclerosing cholangitides like primary sclerosing cholangitis (PSC). Accurate diagnosis is critical to avoid unnecessary surgical interventions.
Objective:
This mini-review aims to synthesize the most current evidence on the pathogenesis, diagnostic pitfalls, and management strategies for IgG4-SC, with a focused discussion on overcoming diagnostic dilemmas and addressing the significant challenge of disease relapse.
Key findings:
The pathogenesis of IgG4-SC involves a complex interplay of genetic predisposition, environmental triggers (e.g., industrial vapors, dust, gases, fumes, and asbestos), and dysregulated adaptive immunity. A distinctive CD4+ T-cell response, dominated by T-helper 2 (Th2), follicular helper T (Tfh) cells, and regulatory T cells (Tregs), drives B-cell activation, oligoclonal expansion of IgG4+ plasmablasts, and progressive fibrosis. Notably, the discovery of IgG4/IgG1 autoantibodies against annexin A11 and laminin 511-E8 has provided insight into potential direct pathogenic mechanisms. Diagnosis relies on a multimodal approach integrating clinical presentation, characteristic imaging findings, elevated serum IgG4 levels (with levels >2× ULN being suggestive, and >4× ULN being highly specific), the IgG4/IgG1 ratio (>0.24), other organ involvement (notably type 1 autoimmune pancreatitis, AIP), supportive histopathology, and a rapid response to corticosteroid therapy. Despite high initial response rates to steroids, relapse occurs in 30%–50% of patients. Maintenance therapy with steroid-sparing immunomodulators (e.g., azathioprine, mycophenolate mofetil) or B-cell depleting agents such as rituximab is often required. The anti-CD19 monoclonal antibody inebilizumab has emerged as a potent new option for maintaining remission.
Conclusion:
Maintaining a high index of clinical suspicion for IgG4-SC is essential in patients with obstructive jaundice and biliary strictures. Future efforts should focus on validating specific biomarkers (e.g., circulating plasmablasts, autoantibody profiles) and developing evidence-based protocols for long-term management to prevent fibrotic complications and reduce the relapse rate.
1 Introduction
Immunoglobulin G4-related sclerosing cholangitis (IgG4-SC), or IgG4-related cholangitis (IRC), is the biliary manifestation of a multi-system fibroinflammatory condition termed IgG4-related disease (IgG4-RD). Initially described in the context of type 1 autoimmune pancreatitis (AIP), it is now recognized as a principal cause of benign biliary strictures that can be radiologically indistinguishable from cholangiocarcinoma (CCA) (1, 2). Historically, misdiagnosis has led to unnecessary pancreaticoduodenectomy or liver resection (3), underscoring the critical importance of accurate diagnosis. The disease is pathologically characterized by lymphoplasmacytic infiltration, storiform fibrosis, obliterative phlebitis, and a significant increase in IgG4-positive plasma cells within the bile duct wall (4).
Although corticosteroid therapy is highly effective in the inflammatory phase, disease relapse is common, and long-term sequelae from progressive fibrosis pose a significant management challenge (5). This review provides a contemporary overview of the immunopathogenesis, clinical and diagnostic features, differential diagnosis, and treatment paradigms of IgG4-SC, with particular emphasis on navigating diagnostic dilemmas and strategies to mitigate relapse. It highlights ongoing controversies and future directions, incorporating insights from the latest international guidelines and clinical trials (6, 7).
2 Unraveling the pathogenesis: a complex immune dysregulation
The precise etiology of IgG4-SC remains elusive; however, current evidence suggests an antigen-driven process in genetically susceptible individuals, often triggered by environmental exposures, leading to a distinctive CD4+ T-cell and B-cell response (8, 9).
2.1 Genetic predisposition and environmental triggers
Genome-wide association studies have identified several risk loci for IgG4-RD, including HLA-DRB1 and non-HLA genes such as FCCR2B and CTL44, indicating roles in antigen presentation and immune regulation (10, 11). Notably, long-term exposure to occupational toxins–specifically industrial vapors, dust, gases, fumes (VDGF), and asbestos–has been established as a significant environmental risk factor, which may contribute to the strong male predominance in IgG4-SC (9, 12). Cigarette smoking has also been associated with an increased risk of IgG4-RD, particularly retroperitoneal fibrosis (13).
2.2 The central and diversified role of T lymphocytes
A dominant T-helper 2 (Th2) and regulatory T cell (Treg) response is a hallmark of IgG4-SC (14). Th2 cytokines (IL-4, IL-5, IL-13) promote B-cell activation, isotype switching, and are implicated in associated eosinophilia. T follicular helper (Tfh) cells, particularly the Th2 subset, facilitate germinal center formation, B-cell differentiation, and IgG4 production (15). T peripheral helper (Tph) cells are also increased and may promote ectopic lymphoid structure formation, specifically tertiary lymphoid structures (TLS), within lesions. Notably, a significant proportion of these Th2-polarized cells express the transcription factor GATA3 and also exhibit cytotoxic T lymphocyte (CTL) markers, blurring the traditional Th2/CTL dichotomy. These GATA3 + CTLs are clonally expanded within lesions and contribute directly to tissue damage via perforin and granzyme secretion, highlighting a unique pathogenic T-cell subset that combines helper and cytotoxic functions (16, 17). Concurrently, an abundance of Tregs (FOXP3+, CD4+, CD25+) within lesions overexpresses IL-10 and TGF-β. While IL-10 contributes to the IgG4 class switch, TGF-β is a potent pro-fibrotic cytokine, directly fueling the tissue fibrosis characteristic of advanced disease (14, 18).
2.3 B cells, plasmablasts and the dual nature of IgG4 antibodies
A robust, oligoclonal B-cell and plasmablast response is evident in active disease, serving as a sensitive biomarker (19, 20). Although tissue infiltration by IgG4-positive plasma cells is a pathological cornerstone, the role of the IgG4 antibody itself is complex. Its unique structural characteristic of “Fab-arm exchange” results in bispecific antibodies with poor immune complex-forming capacity, suggesting it may function as an “anti-inflammatory” antibody (21). However, a paradigm shift has occurred with the identification of specific autoantigens. IgG4 (and IgG1) autoantibodies against annexin A11 and laminin 511-E8 have been demonstrated to be pathogenic in vitro and in animal models, potentially by directly blocking the function of these critical proteins, thereby impairing cholangiocyte protective mechanisms (e.g., the “biliary bicarbonate umbrella”) and contributing to bile duct injury (22, 23). Thus, IgG4 may serve as both a marker of disease and, in specific contexts, a direct mediator of pathology.
2.4 Translational implications for diagnosis and therapy
Understanding this intricate immunopathology directly informs current challenges. The oligoclonal expansion of B-cells and plasmablasts underpins the use of B-cell depletion therapy (e.g., rituximab, inebilizumab) and supports the investigation of circulating plasmablasts as a biomarker for disease activity and relapse risk (24, 25). The identification of pathogenic autoantibodies opens avenues for developing antigen-specific diagnostic assays, though their clinical utility requires further validation (22, 23). Similarly, characterizing dominant T-cell subsets (Th2, Tfh, Tph) offers potential future targets for more precise immunomodulation.
3 Clinical presentation and diagnostic approach
3.1 Clinical, laboratory, and imaging features
The disease predominantly affects middle-aged to elderly males, who frequently present with painless obstructive jaundice, mimicking pancreatic or biliary malignancy (3, 24–26). Many patients have or will develop other organ involvement, most commonly type 1 AIP, but also retroperitoneal fibrosis, sclerosing sialadenitis, and dacryoadenitis (27, 28). Characteristic laboratory findings include elevated serum IgG4 levels (observed in approximately 80% of patients). The IgG4/IgG1 ratio (cut-off > 0.24) can significantly improve diagnostic specificity in cases with moderately elevated IgG4 (1–2× ULN) (29).
Imaging modalities, including CT, MRI/MRCP, and EUS, are crucial. Key features favoring IgG4-SC include long-segment (>3 cm), band-like strictures with concentric, symmetric wall thickening (>2.5 mm) and a smooth inner margin. In contrast, CCA often presents with shorter, asymmetric, mass-like thickening. The absence of significant upstream ductal dilation relative to the degree of stenosis can also be a clue. Magnetic resonance cholangiopancreatography (MRCP) is essential for mapping stricture morphology and distribution. Intraductal ultrasound (IDUS) features, such as circular symmetric wall thickness and a layered “sandwich” pattern, are highly suggestive of IgG4-SC (30, 31). Positron Emission Tomography (PET) with 18F-fluorodeoxyglucose (FDG-PET) can provide valuable functional information in IgG4-SC. PET often demonstrates diffusely increased FDG uptake along the involved bile ducts and in other affected organs (e.g., pancreas, salivary glands), which may help in assessing disease activity, identifying subclinical multi-organ involvement, and monitoring treatment response. However, it is not routinely required for diagnosis and should be interpreted alongside morphological imaging findings (32).
Immunoglobulin G4-related sclerosing cholangitis is classically classified into four types based on stricture location (Table 1) (33). This classification has practical utility, as different types mimic different diseases (e.g., Type 1 vs. pancreatic cancer, Type 4 vs. PSC or hilar CCA).
TABLE 1
| Type | Description of stricture location | Main differential diagnosis |
|---|---|---|
| 1 | Distal third of the common bile duct | Pancreatic cancer, chronic pancreatitis |
| 2 | Intrahepatic ducts, without hilar involvement | Not specified |
| 3 | Hilar and distal common bile duct | Hilar cholangiocarcinoma |
| 4 | Strictures involving both hilar and intrahepatic ducts | Primary sclerosing cholangitis, hilar cholangiocarcinoma |
Cholangiographic classification of IgG4-SC [Nishino T et al. (33)].
3.2 Diagnostic criteria and the role of histology
The HISORt criteria remain a comprehensive diagnostic system, integrating Histology, Imaging, Serology, Other organ involvement, and Response to corticosteroid therapy (34). A definitive diagnosis can be established with characteristic histology [requiring at least two of the following three features: dense lymphoplasmacytic infiltrate, storiform fibrosis, and obliterative phlebitis, supported by >10 IgG4+ plasma cells/HPF in biopsy or >50/HPF in resection specimens (4)] or a combination of typical imaging, elevated serum IgG4 (>2× ULN), and evidence of other organ involvement.
It is critically important to note that an elevated serum IgG4 level alone is not diagnostic. Levels can be modestly elevated in 10%–15% of patients with PSC or CCA (31–36). While a level exceeding four times the upper limit of normal (ULN) is highly specific for IgG4-SC, its sensitivity is low. Therefore, serum IgG4 must always be interpreted within the entire clinical context. Updated international guidelines emphasize a structured diagnostic workflow to categorize patients into “definitive” or “probable” IgG4-SC, with the latter group warranting a diagnostic steroid trial only after malignancy has been rigorously excluded (6, 7).
Given the multifaceted nature of IgG4-SC, no single test is pathognomonic. Therefore, a structured, multimodal diagnostic algorithm is essential to integrate the clinical, serological, radiological, and histological features discussed above. Figure 1 provides a practical diagnostic workflow that synthesizes these components, guiding clinicians from the initial presentation of a biliary stricture toward a definitive or probable diagnosis of IgG4-SC, while emphasizing the critical first step of ruling out malignancy. The subsequent section delves into the practical application of this workflow in differentiating IgG4-SC from its key mimics.
FIGURE 1
Diagnostic algorithm for suspected IgG4-sclerosing cholangitis. *Pathognomonic histology from bile duct/liver biopsy requires ≥2 of: dense lymphoplasmacytic infiltrate, storiform fibrosis, obliterative phlebitis, and >10 IgG4+ plasma cells per high-power field. AIP, autoimmune pancreatitis; CCA, cholangiocarcinoma; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound; FNA, fine-needle aspiration; HPF, high-power field; MRCP, magnetic resonance cholangiopancreatography; PSC, primary sclerosing cholangitis; ULN, upper limit of normal.
4 Navigating the differential diagnosis
The differentiation of IgG4-SC from its mimics is a common clinical dilemma, necessitating a multimodal approach.
4.1 IgG4-SC vs. cholangiocarcinoma (CCA)
This distinction is paramount. Clinically, the presence of other IgG4-RD manifestations strongly favors IgG4-SC. Serologically, a serum IgG4 level >2× ULN supports IgG4-SC, and specificity increases significantly at levels >4× ULN. The IgG4/IgG1 ratio is also useful (27–29). On imaging, IgG4-SC often presents with longer, smoother strictures and more diffuse, symmetric bile duct wall thickening compared to the asymmetric, mass-like thickening often seen in CCA. Histologically, bile duct biopsies showing a characteristic lymphoplasmacytic infiltrate with abundant IgG4-positive plasma cells and absence of atypia support IgG4-SC. Finally, a carefully monitored 2- to 4-weeks diagnostic corticosteroid trial can be employed, which typically leads to symptomatic, biochemical, and radiological improvement in IgG4-SC but not in CCA; this approach, however, should only be considered after malignancy has been rigorously investigated and excluded (6).
4.2 IgG4-SC vs. primary sclerosing cholangitis (PSC)
The distinction between these two sclerosing cholangitides is critical. Key differences include the older age of onset and male predominance in IgG4-SC, the strong association of PSC with inflammatory bowel disease (IBD), the presence of other organ involvement in IgG4-SC, and the dramatic response of IgG4-SC to corticosteroid therapy, which is ineffective in PSC. Imaging features such as the absence of “pruning” and the presence of long, band-like strictures also favor IgG4-SC (37). Novel serum metabolomic panels, which profile small-molecule metabolites to distinguish disease states, show promise in improving this differentiation (38).
5 Treatment strategies and the challenge of relapse
5.1 Induction of remission
Corticosteroids constitute the first-line therapy for active IgG4-SC. A standard induction regimen is oral prednisolone (0.5–0.6 mg/kg/day) for 2–4 weeks, followed by a gradual taper over 2–3 months (5, 6). Rapid improvement in symptoms, biochemistry, and imaging is typically observed and serves as a diagnostic confirmation. Medium-dose prednisone has been shown to be as effective as high dose for remission induction (39). For patients with severe obstructive jaundice, biliary stenting via ERCP may be necessary prior to initiating steroid therapy.
5.2 Managing relapse and maintenance therapy
Disease relapse occurs in 30%–50% of patients, often during steroid taper or after discontinuation (5). Risk factors include proximal (hilar/intrahepatic) strictures, persistent bile duct wall thickening on imaging, and persistently elevated serum IgG4 (5, 40).
5.2.1 Steroid-sparing immunomodulators
For relapsing disease, steroid dependence, or as part of an initial maintenance strategy, agents such as azathioprine (1.5–2.5 mg/kg/day) or mycophenolate mofetil are commonly employed. Combination therapy with glucocorticoids is associated with higher remission rates than steroids alone (40, 41).
5.2.2 B-cell depleting therapy
The anti-CD20 monoclonal antibody rituximab is highly effective for inducing and maintaining remission, both in relapsing/refractory disease and as a first-line steroid-sparing agent (42, 43). More recently, the anti-CD19 monoclonal antibody inebilizumab demonstrated significant efficacy in reducing relapse risk in a phase 3 randomized controlled trial, confirming the central role of B-cell depletion (44). Beyond rituximab and inebilizumab, several novel agents are under investigation in ongoing clinical trials. These include other B-cell-targeting therapies, agents targeting specific cytokines or T-cell pathways, and antifibrotic compounds. The results of these trials are awaited to further expand the therapeutic arsenal for IgG4-SC (44, 45).
The decision regarding the duration of maintenance therapy is individualized, but current evidence supports a minimum of 3 years, with longer-term treatment considered for high-risk patients (6, 43). The overall strategy for induction and maintenance therapy, incorporating the options for steroid-sparing agents and B-cell depletion, is summarized in Figure 2.
FIGURE 2
Treatment pathway for IgG4-sclerosing cholangitis. ERCP, endoscopic retrograde cholangiopancreatography; IgG4-SC, Immunoglobulin G4-related sclerosing cholangitis.
6 Conclusion and future perspectives
Immunoglobulin G4-related sclerosing cholangitis is a unique biliary disease that sits at the intersection of hepatology, gastroenterology, rheumatology, and immunology. This review has emphasized the critical importance of recognizing its mimicker status to prevent misdiagnosis and unnecessary procedures. While significant progress has been made–particularly in elucidating its complex immune pathogenesis, identifying environmental triggers and specific autoantigens, and establishing multimodal diagnostic criteria–several challenges remain. The high relapse rate underscores the need for superior biomarkers (e.g., circulating plasmablasts, memory B cells) to predict disease course and guide maintenance therapy. Future research should be directed toward: (1) Identifying antigens: unraveling the initial disease-triggering antigens and their role in breaking immune tolerance. (2) Validating biomarkers: developing and validating non-invasive biomarkers for diagnosis, monitoring disease activity, and predicting relapse. (3) Optimizing treatment: conducting large, randomized controlled trials to establish optimal steroid-sparing regimens, define the long-term role of B-cell-targeted therapies, and explore novel strategies to reverse or halt established fibrosis.
Statements
Author contributions
XR: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. XJ: Conceptualization, Data curation, Investigation, Methodology, Writing – review & editing. LL: Data curation, Investigation, Methodology, Project administration, Writing – review & editing. MZ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Software, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This study was supported by Research Fund of Affiliated Hospital of Hebei University (No. 2025Q08).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
Kamisawa T Nakazawa T Tazuma S Zen Y Tanaka A Ohara H et al Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci. (2019) 26:9–42. 10.1002/jhbp.596
2.
Kersten R Trampert DC Herta T Hubers LM Maillette de Buy Wenniger LJ Verheij J et al IgG4-related cholangitis - a mimicker of fibrosing and malignant cholangiopathies. J Hepatol. (2023) 79:1502–23. 10.1016/j.jhep.2023.08.005
3.
Ghazale A Chari ST Zhang L Smyrk TC Takahashi N Levy MJ et al Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. (2008) 134:706–15. 10.1053/j.gastro.2007.12.009
4.
Deshpande V Zen Y Chan JK Yi EE Sato Y Yoshino T et al Consensus statement on the pathology of IgG4-related disease. Mod Pathol. (2012) 25:1181–92. 10.1038/modpathol.2012.72
5.
Hart PA Topazian MD Witzig TE Clain JE Gleeson FC Klebig RR et al Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. (2013) 62:1607–15. 10.1136/gutjnl-2012-302886
6.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. (2022) 77:761–806. 10.1016/j.jhep.2022.05.011
7.
Löhr JM Beuers U Vujasinovic M Alvaro D Frøkjær JB Buttgereit F et al European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. United European Gastroenterol J. (2020) 8:637–66. 10.1177/2050640620934911
8.
Pillai S Perugino C Kaneko N . Immune mechanisms of fibrosis and inflammation in IgG4-related disease.Curr Opin Rheumatol. (2020) 32:146–51. 10.1097/BOR.0000000000000686
9.
Hubers LM Schuurman AR Buijs J Mostafavi N Bruno MJ Vermeulen RCH et al Blue-collar work is a risk factor for developing IgG4-related disease of the biliary tract and pancreas. JHEP Rep. (2021) 3:100385. 10.1016/j.jhepr.2021.100385
10.
Terao C Ota M Iwasaki T Shiokawa M Kawaguchi S Kuriyama K et al IgG4-related disease in the Japanese population: a genome-wide association study. Lancet Rheumatol. (2019) 1:e14–22. 10.1016/S2665-9913(19)30006-2
11.
Ishikawa Y Terao C . Genetic analysis of IgG4-related disease.Mod Rheumatol. (2020) 30:17–23. 10.1080/14397595.2019.1621000
12.
de Buy Wenniger LJ Culver EL Beuers U . Exposure to occupational antigens might predispose to IgG4-related disease.Hepatology. (2014) 60:1453–4. 10.1002/hep.26999
13.
Wallwork R Perugino CA Fu X Harkness T Zhang Y Choi HK et al The association of smoking with immunoglobulin G4-related disease: a case-control study. Rheumatology. (2021) 60:5310–7. 10.1093/rheumatology/keab172
14.
Zen Y Fujii T Harada K Kawano M Yamada K Takahira M et al Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. (2007) 45:1538–46. 10.1002/hep.21697
15.
Akiyama M Suzuki K Yasuoka H Kaneko Y Yamaoka K Takeuchi T . Follicular helper T cells in the pathogenesis of IgG4-related disease.Rheumatology. (2018) 57:236–45. 10.1093/rheumatology/kex171
16.
Mattoo H Mahajan VS Maehara T Deshpande V Della-Torre E Wallace ZS et al Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol. (2016) 138:825–38. 10.1016/j.jaci.2015.12.1330
17.
Perugino CA Kaneko N Maehara T Mattoo H Kers J Allard-Chamard H et al CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease. J Allergy Clin Immunol. (2021) 147:368–82. 10.1016/j.jaci.2020.05.022
18.
Della-Torre E Lanzillotta M Doglioni C . Immunology of IgG4-related disease.Clin Exp Immunol. (2015) 181:191–206. 10.1111/cei.12641
19.
Maillette de Buy Wenniger LJ Doorenspleet ME Klarenbeek PL Verheij J Baas F Elferink RP et al Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology. (2013) 57:2390–8. 10.1002/hep.26232
20.
Wallace ZS Mattoo H Carruthers M Mahajan VS Della Torre E Lee H et al Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. (2015) 74:190–5. 10.1136/annrheumdis-2014-205233
21.
Rispens T Huijbers MG . The unique properties of IgG4 and its roles in health and disease.Nat Rev Immunol. (2023) 23:763–78. 10.1038/s41577-023-00871-z
22.
Hubers LM Vos H Schuurman AR Erken R Oude Elferink RP Burgering B et al Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. Gut. (2018) 67:728–35. 10.1136/gutjnl-2017-314548
23.
Herta T Kersten R Chang JC Hubers L Go S Tolenaars D et al Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection. J Hepatol. (2022) 76:319–31. 10.1016/j.jhep.2021.10.009
24.
Lanzillotta M Ramirez GA Milani R Dagna L Della-Torre EB . cell depletion after treatment with rituximab predicts relapse of IgG4-related disease.Rheumatology. (2025) 64:2290–4. 10.1093/rheumatology/keae248
25.
Khosroshahi A Wallace ZS Crowe JL Akamizu T Azumi A Carruthers MN et al International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. (2015) 67:1688–99. 10.1002/art.39132
26.
Löhr JM Vujasinovic M Rosendahl J Stone JH Beuers U . IgG4-related diseases of the digestive tract.Nat Rev Gastroenterol Hepatol. (2022) 19:185–97. 10.1038/s41575-021-00529-y
27.
Hamano H Kawa S Horiuchi A Unno H Furuya N Akamatsu T et al High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. (2001) 344:732–8. 10.1056/NEJM200103083441005
28.
Stone JH Zen Y Deshpande V . IgG4-related disease.N Engl J Med. (2012) 366:539–51. 10.1056/NEJMra1104650
29.
Boonstra K Culver EL de Buy Wenniger LM van Heerde MJ van Erpecum KJ Poen AC et al Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology. (2014) 59:1954–63. 10.1002/hep.26977
30.
Nakazawa T Naitoh I Hayashi K Okumura F Miyabe K Yoshida M et al Diagnostic criteria for IgG4-related sclerosing cholangitis based on cholangiographic classification. J Gastroenterol. (2012) 47:79–87. 10.1007/s00535-011-0465-z
31.
Naitoh I Yoshida M Nakazawa T . Endoscopic diagnosis of immunoglobulin G4-related sclerosing cholangitis.Dig Endosc. (2025) 37:824–33. 10.1111/den.15039
32.
Zhang J Chen H Ma Y Xiao Y Niu N Lin W et al Characterizing IgG4-related disease with 18F-FDG PET/CT: a prospective cohort study. Eur J Nucl Med Mol Imaging. (2014) 41:1624–34. 10.1007/s00259-014-2729-3
33.
Nishino T Oyama H Hashimoto E Toki F Oi I Kobayashi M et al Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J Gastroenterol. (2007) 42:550–9. 10.1007/s00535-007-2038-8
34.
Kim MH Kwon S . Diagnostic criteria for autoimmune chronic pancreatitis.J Gastroenterol. (2007) 42(Suppl 18):42–9. 10.1007/s00535-007-2050-z
35.
Björnsson E Chari ST Smyrk TC Lindor K . Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature.Hepatology. (2007) 45:1547–54. 10.1002/hep.21685
36.
Oseini AM Chaiteerakij R Shire AM Ghazale A Kaiya J Moser CD et al Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology. (2011) 54:940–8. 10.1002/hep.24487
37.
Tokala A Khalili K Menezes R Hirschfield G Jhaveri KS . Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis.AJR Am J Roentgenol. (2014) 202:536–43. 10.2214/AJR.12.10360
38.
Radford-Smith DE Selvaraj EA Peters R Orrell M Bolon J Anthony DC et al A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis. Liver Int. (2022) 42:1344–54. 10.1111/liv.15192
39.
Wu Q Chang J Chen H Chen Y Yang H Fei Y et al Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial. Int J Rheum Dis. (2017) 20:639–46. 10.1111/1756-185X.13088
40.
Kubota K Watanabe S Uchiyama T Kato S Sekino Y Suzuki K et al Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Gastroenterol. (2011) 46:834–42. 10.1007/s00535-011-0393-y
41.
Omar D Chen Y Cong Y Dong L . Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis.Rheumatology. (2020) 59:718–26. 10.1093/rheumatology/kez380
42.
Carruthers MN Topazian MD Khosroshahi A Witzig TE Wallace ZS Hart PA et al Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. (2015) 74:1171–7. 10.1136/annrheumdis-2014-206605
43.
Majumder S Mohapatra S Lennon RJ Piovezani Ramos G Postier N Gleeson FC et al Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease. Clin Gastroenterol Hepatol. (2018) 16:1947–53. 10.1016/j.cgh.2018.02.049
44.
Stone JH Khosroshahi A Zhang W Della Torre E Okazaki K Tanaka Y et al Inebilizumab for treatment of IgG4-related disease. N Engl J Med. (2024) 392:1168–77. 10.1056/NEJMoa2409712
45.
Xu J Zhai J Zhao J . Pathogenic roles of follicular helper T cells in IgG4-related disease and implications for potential therapy.Front Immunol. (2024) 15:1413860. 10.3389/fimmu.2024.1413860
Summary
Keywords
autoimmune pancreatitis, corticosteroid therapy, diagnosis, differential diagnosis, IgG4-related cholangitis, IgG4-related sclerosing cholangitis, inebilizumab, relapse
Citation
Ren X, Jin X, Liu L and Zhang M (2026) IgG4-related sclerosing cholangitis: navigating diagnostic dilemmas and the challenge of relapse. Front. Med. 13:1732637. doi: 10.3389/fmed.2026.1732637
Received
26 October 2025
Revised
09 January 2026
Accepted
12 January 2026
Published
05 February 2026
Volume
13 - 2026
Edited by
Marco Lanzillotta, Vita-Salute San Raffaele University, Italy
Reviewed by
Alexey Okhlobystin, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Russia
Updates
Copyright
© 2026 Ren, Jin, Liu and Zhang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiangxiang Ren, 15369312891@163.comMeng Zhang, pfkzm1991@163.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.